ABBV is a High Yield Growth Stock on the move.
ABBV engages in the discovery, development, manufacture, and sale of pharmaceuticals worldwide. The company's offerings include pharmaceutical products such as autoimmune and intestinal disease therapy, HUMIRA, adult plaque psoriasis treatment, SKYRIZI, and adult rheumatoid arthritis treatment, RINVOQ.
On December 8, Allergan, an ABBV company, announced that its product VUITYâ„¢, the first U.S. Food and Drug Administration (FDA) approved eye drop to treat presbyopia, is now available by prescription in pharmacies nationwide. This should add to the company's revenue stream.
On December 6, ABBV announced positive top-line results from its U-EXCEED phase-3 induction study regarding the usage of Upadacitinib (RINVOQ®) to treat Crohn's disease. This demonstrates the company's expertise and should enable the company to cater to patients with this disease.
ABBV engages in the discovery, development, manufacture, and sale of pharmaceuticals worldwide. The company's offerings include pharmaceutical products such as autoimmune and intestinal disease therapy, HUMIRA, adult plaque psoriasis treatment, SKYRIZI, and adult rheumatoid arthritis treatment, RINVOQ.
On December 8, Allergan, an ABBV company, announced that its product VUITYâ„¢, the first U.S. Food and Drug Administration (FDA) approved eye drop to treat presbyopia, is now available by prescription in pharmacies nationwide. This should add to the company's revenue stream.
On December 6, ABBV announced positive top-line results from its U-EXCEED phase-3 induction study regarding the usage of Upadacitinib (RINVOQ®) to treat Crohn's disease. This demonstrates the company's expertise and should enable the company to cater to patients with this disease.